Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3543 - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status – putative targets


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site

Thoracic Malignancies


Vilde Haakensen


Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268


V.D. Haakensen1, A. Khadse2, V. Sandhu-Baveja2, A.R. Halvorsen2, L.H. Jørgensen3, S. Solberg3, O.T. Brustugun4, E. Kure2, A. Helland1

Author affiliations

  • 1 Institute For Cancer Research And Dept Of Oncology, Oslo University Hospital, N-0424 - Oslo/NO
  • 2 Dept Of Cancer Genetics, Institute For Cancer Research, Oslo University Hospital, 0310 - Oslo/NO
  • 3 Departement Of Thoracic Surgery, Oslo University Hospital, 0372 - Oslo/NO
  • 4 Oncology, Radiumhospitalet, 0379 - Oslo/NO


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3543


Non-small cell lung cancer is a major killer world-wide. While some lung adenocarcinomas have mutations qualifying for targeted therapy, this is not the case for the squamous cell carcinomas (SqCC). TP53 mutations exist in around 85% of squamous cell carcinomas, but the mutations are difficult to target directly. We explore the biology of TP53 mutated SqCC and search for putative targets for therapy.


Patients undergoing surgery for squamous cell lung carcinoma from 2006 to 2015 were included in the study (n = 198). Tumours were analysed using Illumina SNP6 for copy number alterations and Agilent 60K arrays for gene expression. TP53 mutations were analysed by Sanger sequencing. For 140 patients both gene expression and copy number data were available.


Frequency plots for tumours harbouring TP53 mutations and TP53 wild type tumours were generated separately identifying genomic regions with differential frequency of copy number alterations. TP53 mutations are more frequent in the previously published gene expression subtypes Classical and Primitive compared with Basal and Secretory, but this does not seem to affect survival. Amplifications are particularly frequent in the Classical subtype. Target gene search was performed, identifying 148 genes with amplification and over-expression in TP53 mutated tumours compared with wild type tumours. Several of these putative target genes are previously studied as putative targets of therapy. The majority of the putative target genes are located on the chromosomal arms 2p for samples of the Secretory subtype, 2q for samples of the Primitive subtype and on 12p and 17q for samples of the Classical subtype.


There are distinct copy number alterations and gene expression patterns in TP53 mutated squamous cell lung cancers that can be used to identify novel targets of therapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Oslo University Hospital.


The Norwegian Cancer Society, South-Eastern Norway Regional Health Authority.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.